TY - JOUR
T1 - The global burden of non-typhoidal salmonella invasive disease
T2 - a systematic analysis for the Global Burden of Disease Study 2017
AU - Stanaway, Jeffrey D.
AU - Parisi, Andrea
AU - Sarkar, Kaushik
AU - Blacker, Brigette F.
AU - Reiner, Robert C.
AU - Hay, Simon I.
AU - Nixon, Molly R.
AU - Dolecek, Christiane
AU - James, Spencer L.
AU - Mokdad, Ali H.
AU - Abebe, Getaneh
AU - Ahmadian, Elham
AU - Alahdab, Fares
AU - Alemnew, Birhan Tamene T.
AU - Alipour, Vahid
AU - Allah Bakeshei, Fatemeh
AU - Animut, Megbaru Debalkie
AU - Ansari, Fereshteh
AU - Arabloo, Jalal
AU - Asfaw, Ephrem Tsegay
AU - Bagherzadeh, Mojtaba
AU - Bassat, Quique
AU - Belayneh, Yaschilal Muche Muche
AU - Carvalho, Félix
AU - Daryani, Ahmad
AU - Demeke, Feleke Mekonnen
AU - Demis, Asmamaw Bizuneh Bizuneh
AU - Dubey, Manisha
AU - Duken, Eyasu Ejeta
AU - Dunachie, Susanna J.
AU - Eftekhari, Aziz
AU - Fernandes, Eduarda
AU - Fouladi Fard, Reza
AU - Gedefaw, Getnet Azeze
AU - Geta, Birhanu
AU - Gibney, Katherine B.
AU - Hasanzadeh, Amir
AU - Hoang, Chi Linh
AU - Kasaeian, Amir
AU - Khater, Amir
AU - Kidanemariam, Zelalem Teklemariam
AU - Lakew, Ayenew Molla
AU - Malekzadeh, Reza
AU - Melese, Addisu
AU - Mengistu, Desalegn Tadese
AU - Mestrovic, Tomislav
AU - Miazgowski, Bartosz
AU - Mohammad, Karzan Abdulmuhsin
AU - Mohammadian, Mahdi
AU - Mohammadian-Hafshejani, Abdollah
AU - Nguyen, Cuong Tat
AU - Nguyen, Long Hoang
AU - Nguyen, Son Hoang
AU - Nirayo, Yirga Legesse
AU - Olagunju, Andrew T.
AU - Olagunju, Tinuke O.
AU - Pourjafar, Hadi
AU - Qorbani, Mostafa
AU - Rabiee, Mohammad
AU - Rabiee, Navid
AU - Rafay, Anwar
AU - Rezapour, Aziz
AU - Samy, Abdallah M.
AU - Sepanlou, Sadaf G.
AU - Shaikh, Masood Ali
AU - Sharif, Mehdi
AU - Shigematsu, Mika
AU - Tessema, Belay
AU - Tran, Bach Xuan
AU - Ullah, Irfan
AU - Yimer, Ebrahim M.
AU - Zaidi, Zoubida
AU - Murray, Christopher J.L.
AU - Crump, John A.
N1 - Funding Information:
Funding for this analysis was provided by the Bill & Melinda Gates Foundation (grant number OPP1132415). We acknowledge the financial support provided by the Endeavour Scholarship (to AP). We also thank Jackie Cao for her help with the translation of Chinese articles. FC acknowledges grant UID/MULTI/04378/2019 and UID/QUI/50006/2019 support with funding from FCT/MCTES through national funds. EF acknowledges grant UID/MULTI/04378/2019 and UID/QUI/50006/2019 support with funding from FCT/MCTES through national funds. KBG receives salary support for the National Health and Medical Research Council (NHMRC). AMS received a fellowship from the Egyptian Fulbright Mission Program (EFMP).
Funding Information:
Funding for this analysis was provided by the Bill & Melinda Gates Foundation ( grant number OPP1132415 ). We acknowledge the financial support provided by the Endeavour Scholarship (to AP). We also thank Jackie Cao for her help with the translation of Chinese articles. FC acknowledges grant UID/MULTI/04378/2019 and UID/QUI/50006/2019 support with funding from FCT/MCTES through national funds. EF acknowledges grant UID/MULTI/04378/2019 and UID/QUI/50006/2019 support with funding from FCT/MCTES through national funds. KBG receives salary support for the National Health and Medical Research Council (NHMRC). AMS received a fellowship from the Egyptian Fulbright Mission Program (EFMP).
Publisher Copyright:
© 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2019/12
Y1 - 2019/12
N2 - Background: Non-typhoidal salmonella invasive disease is a major cause of global morbidity and mortality. Malnourished children, those with recent malaria or sickle-cell anaemia, and adults with HIV infection are at particularly high risk of disease. We sought to estimate the burden of disease attributable to non-typhoidal salmonella invasive disease for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017. Methods: We did a systematic review of scientific databases and grey literature, and estimated non-typhoidal salmonella invasive disease incidence and mortality for the years 1990 to 2017, by age, sex, and geographical location using DisMod-MR, a Bayesian meta-regression tool. We estimated case fatality by age, HIV status, and sociodemographic development. We also calculated the HIV-attributable fraction and estimated health gap metrics, including disability-adjusted life-years (DALYs). Findings: We estimated that 535 000 (95% uncertainty interval 409 000–705 000) cases of non-typhoidal salmonella invasive disease occurred in 2017, with the highest incidence in sub-Saharan Africa (34·5 [26·6–45·0] cases per 100 000 person-years) and in children younger than 5 years (34·3 [23·2–54·7] cases per 100 000 person-years). 77 500 (46 400–123 000) deaths were estimated in 2017, of which 18 400 (12 000–27 700) were attributable to HIV. The remaining 59 100 (33 300–98 100) deaths not attributable to HIV accounted for 4·26 million (2·38–7·38) DALYs in 2017. Mean all-age case fatality was 14·5% (9·2–21·1), with higher estimates among children younger than 5 years (13·5% [8·4–19·8]) and elderly people (51·2% [30·2–72·9] among those aged ≥70 years), people with HIV infection (41·8% [30·0–54·0]), and in areas of low sociodemographic development (eg, 15·8% [10·0–22·9] in sub-Saharan Africa). Interpretation: We present the first global estimates of non-typhoidal salmonella invasive disease that have been produced as part of GBD 2017. Given the high disease burden, particularly in children, elderly people, and people with HIV infection, investigating the sources and transmission pathways of non-typhoidal salmonella invasive disease is crucial to implement effective preventive and control measures. Funding: Bill & Melinda Gates Foundation.
AB - Background: Non-typhoidal salmonella invasive disease is a major cause of global morbidity and mortality. Malnourished children, those with recent malaria or sickle-cell anaemia, and adults with HIV infection are at particularly high risk of disease. We sought to estimate the burden of disease attributable to non-typhoidal salmonella invasive disease for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017. Methods: We did a systematic review of scientific databases and grey literature, and estimated non-typhoidal salmonella invasive disease incidence and mortality for the years 1990 to 2017, by age, sex, and geographical location using DisMod-MR, a Bayesian meta-regression tool. We estimated case fatality by age, HIV status, and sociodemographic development. We also calculated the HIV-attributable fraction and estimated health gap metrics, including disability-adjusted life-years (DALYs). Findings: We estimated that 535 000 (95% uncertainty interval 409 000–705 000) cases of non-typhoidal salmonella invasive disease occurred in 2017, with the highest incidence in sub-Saharan Africa (34·5 [26·6–45·0] cases per 100 000 person-years) and in children younger than 5 years (34·3 [23·2–54·7] cases per 100 000 person-years). 77 500 (46 400–123 000) deaths were estimated in 2017, of which 18 400 (12 000–27 700) were attributable to HIV. The remaining 59 100 (33 300–98 100) deaths not attributable to HIV accounted for 4·26 million (2·38–7·38) DALYs in 2017. Mean all-age case fatality was 14·5% (9·2–21·1), with higher estimates among children younger than 5 years (13·5% [8·4–19·8]) and elderly people (51·2% [30·2–72·9] among those aged ≥70 years), people with HIV infection (41·8% [30·0–54·0]), and in areas of low sociodemographic development (eg, 15·8% [10·0–22·9] in sub-Saharan Africa). Interpretation: We present the first global estimates of non-typhoidal salmonella invasive disease that have been produced as part of GBD 2017. Given the high disease burden, particularly in children, elderly people, and people with HIV infection, investigating the sources and transmission pathways of non-typhoidal salmonella invasive disease is crucial to implement effective preventive and control measures. Funding: Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85075518949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075518949&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(19)30418-9
DO - 10.1016/S1473-3099(19)30418-9
M3 - Article
C2 - 31562022
AN - SCOPUS:85075518949
VL - 19
SP - 1312
EP - 1324
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
SN - 1473-3099
IS - 12
ER -